Entero Healthcare: Consolidating India's fragmented pharma distribution
Consolidating India's Fragmented Pharma Distribution - deep dive into Entero's M&A strategy and healthcare distribution network
Before we begin - a quick note. I recently launched my first product, Growth Triggers. It started as a personal system to track earnings calls and growth drivers and has now turned into a live database covering 1000+ Indian companies, with growth catalysts, guidance filters, and relative strength scans.
If you want to see what I’ve been building, you can check the launch post here
Now, let’s get into today’s piece.
Entero Healthcare distributes pharmaceutical and healthcare products across India. The company was incorporated in January 2018 by Prabhat Agarwal, former CEO of Alkem Labs, and Prem Sethi, former Director at IQVIA. Their goal was simple: create an organized, technology-driven healthcare distribution platform in a market dominated by small, local players.
Since inception, Entero has become one of the three national healthcare product distributors in India. The other two are Keimed (owned by Apollo HealthCo) and API Holdings (PharmEasy). Together, these three hold 8-10% of the overall healthcare distribution market. The remaining 90-92% sits with approximately 65,000 traditional local distributors.
Market Share: National vs Local Distributors
Entero operates 104 warehouses spread across 45 Indian cities. The network delivers to 492 districts in 20 states. It serves 86,200+ retail pharmacies and 3,200+ hospitals. The company distributes 76,600+ SKUs from more than 2,500 healthcare product manufacturers.
What Entero Does
The business model has two components: demand fulfilment and commercial solutions.
On the demand fulfilment side, Entero acts as a B2B distributor. It procures pharmaceuticals, nutraceuticals, OTC products, vaccines, medical devices, and consumables from manufacturers. It then distributes these products to retail pharmacies, hospitals, and clinics across India. The company also sells private-label products including nebulisers, digital thermometers, blood pressure monitors, and adult diapers.
The commercial solutions side involves marketing and promotional services for manufacturers. Entero deploys medical representatives to promote healthcare brands to doctors. It develops marketing strategies and channel management to increase product reach. The company has exclusive agreements with manufacturers for promotion, marketing, and distribution of specific brands.
Entero has a partnership with Roche, signed in 2020, for four nephrology drugs. It has another arrangement with a large MNC pharma company for a cardiac device product. These relationships involve promotion, marketing, and distribution. They carry higher margins than pure distribution work.
The Distribution Network
The network has expanded substantially since FY21.
Revenue per square foot of warehouse space has grown at 11% annually over the past four years. This indicates improving utilisation of the distribution infrastructure.
The geographic spread covers major metros and tier-2 cities. The network reaches Mumbai, Delhi, Hyderabad, Pune, Ahmedabad, Kolkata, Chennai, Bangalore, Lucknow, Jaipur, Indore, Bhubaneswar, Guwahati, Patna, Varanasi, Kochi, Coimbatore, Madurai, Visakhapatnam, Goa, Mangaluru, Raipur, Gorakhpur, Dehradun, Amritsar, Panchkula, Karnal, Ghaziabad, Faridabad, Gurgaon, Ujjain, Vadodara, Tirupathi, Vijayawada, Rajahmundry, Khammam, Karimnagar, Kalaburagi, Bijapur, Belagavi, Davanagere, Mysuru, Kozhikode, Kollam, and dozens of other cities.
Technology Infrastructure
Entero has built four proprietary technology platforms that run its operations.
Entero Direct is a cloud-based application for retail pharmacies. It handles order management, tracking, returns, and claims settlement. Pharmacies can see real-time inventory and order status. The platform includes loyalty programs to improve retailer retention. The sales force uses it to plan customer visits, check live inventory, and view ongoing promotions. The delivery fleet uses it to plan deliveries and update delivery status.
Key features include:
Easy one-touch ordering
Consolidated view of ledger and payments
Complete visibility of all pharma company schemes
Visibility of order and order status
Live inventory visibility for entire product catalogue
Ability to run banner ad campaigns for brands or companies
Loyalty points program
Entero CRM is the customer relationship management tool. Call centre executives can access customer details including past billings and outstanding payments during interactions. The application tracks all customer calling schedules and missed calls. It provides performance dashboards showing call summaries, task summaries, and order metrics.
Entero ERP is a cloud-based enterprise resource planning system implemented across multiple locations. Key benefits include:
Seamless integration of data across locations
Complete control over product and customer masters
Enhanced security features such as web application firewalls
Better centralised controls
Lower risk of data loss
Teqtic is a cloud-based data warehouse and business intelligence tool. It generates customised reports for sales, purchases, and inventory levels across distributors and warehouses. It provides identity-based access control to customers. Manufacturers can access secondary sales data, brand performance overviews, and customer insights at a micro-market level.
The platform shows percentage share of top SKUs for specific molecules, inventory levels by product, and shelf life analysis. This data helps manufacturers optimise their sales operations.
These platforms give Entero visibility across its operations and provide data services to manufacturers. A local distributor with 100-500 retailers and basic ERP tools cannot offer this.
The India Pharma Distribution Market
Market Size and Structure
Pharmaceutical Supply Chain Overview
India has approximately 3,000 pharmaceutical companies manufacturing products in over 10,500 industrial units. These supply through 65,000 distributors to approximately 900,000 private retail chemists.
The market structure differs from developed countries.
Market Share Comparison: India vs Developed Markets
Pre-2015, India’s large/national players held only 3-5% share. This improved to 8-10% currently and is expected to reach 20-30% by FY28. Around 25-30% of pharma distribution volume concentrates in tier-1 cities (Mumbai, Delhi, Hyderabad, Pune, Ahmedabad, Kolkata, Chennai, and Bangalore). Tier-2 cities and beyond remain relatively under penetrated by national distributors.
Why Consolidation Makes Sense
The shift toward national distributors benefits both manufacturers and retailers.
For manufacturers, working with fewer large distributors reduces operational complexity. A pharmaceutical company currently maintains relationships with thousands of distributors across the value chain. Consolidating to a handful of national partners simplifies procurement, billing, claims settlement, and communication. Logistics costs run 4-6% of revenue for the industry. Streamlined procurement and distribution through large players can reduce these costs.
Large distributors can also offer marketing services. They have relationships with healthcare professionals and field representatives. They have reach into regional markets and connections with retail pharmacies and hospitals. Pharmaceutical companies spend 4-5% of revenue on marketing and promotion. This implies Rs80-90 billion of annual marketing expenditure in the Indian pharmaceutical sector. National distributors can capture a portion of this spending by offering promotional services.
For retail pharmacies, large distributors offer higher fill rates and better service.
Operational Advantages: Large vs Local Distributors
Typical Cost Structure of Pharma Distribution
The primary cost for pharma distributors remains procurement of traded goods at approximately 90% of total sales. With such thin margins, scale improves profitability because larger distributors have better bargaining power with suppliers and spread fixed costs over higher volumes.
Data as a Competitive Advantage
Micro-market and regional sales data matter to pharmaceutical companies. This information reveals market demand, customer preferences, demand-supply dynamics, and product performance. Companies use it to identify target areas and tailor strategies.
Distributors that compile secondary data on these aspects become valuable information sources. They track micro-market trends, brand performance, and sales data at the company level. Large distributors with sophisticated technology platforms can provide this data systematically. Local distributors with basic ERP tools cannot.
Entero’s Teqtic platform provides this capability. It generates reports showing sales and shelf life of available inventory for specific molecule strengths. It shows percentage share of top SKUs, inventory levels, and product performance across markets.
Supply Chain Simplification
Traditional pharma supply chains with many small distributors create complexity. A manufacturer selling through 500 distributors manages 500 relationships, 500 invoicing processes, 500 claims settlements, and 500 data collection efforts. Each transaction adds friction. The diagram of traditional distribution shows multiple criss-crossing lines between manufacturers and retail pharmacies, with numerous small distributors in between.
Large national distributors simplify this structure. A manufacturer working with three national players manages three relationships instead of 500. The flow becomes streamlined: manufacturers connect to a single large/national distributor, which then connects to multiple retail pharmacies. Procurement, billing, and data collection become efficient.
This simplification drives manufacturer preference for large distributors. It also creates barriers for local players trying to regain lost relationships.
Keimed: The Market Leader
Keimed is India’s largest pharma distributor with more than twice the revenue of the nearest competitor. It was previously owned by the promoters of Apollo Pharmacy and is now part of Apollo HealthCo. Keimed serves 70,000+ high-performing pharmacies across 18 states. It operates 96 distribution centres with cold chain infrastructure. It has 300+ manufacturer relationships and offers 45,000+ SKUs. Warehouse space totals 600,000 sq. ft. Revenue reached Rs103 billion in FY24, having grown at 20% annually over FY21-24. Reported Ebitda margins were 3.4% in FY24.
Keimed is the preferred distributor for Apollo Healthcare Enterprises Limited (AHEL). Shobana Kamineni, a promoter of Keimed, is the Executive Vice Chairperson of AHEL. AHEL and related entities contributed 54% of Keimed’s revenue in FY24, up from 49% in FY23. This relationship affects margins. Keimed provides preferential pricing to Apollo, which reduces margins by 1-1.5%. Adjusting for this, Keimed’s Ebitda margins would be 4.5-5.0%.
Entero vs Keimed Comparison
The warehouse capacity is similar. The SKU count is higher for Entero. The manufacturer relationships are far more extensive for Entero.
Entero’s Acquisition Strategy
Entero has acquired 45 entities since inception.
The selection criteria include:
Expertise in the domain in which Entero operates or wishes to expand
Strategic fit with existing business such that businesses are synergistic
New retail chemist customers/users that Entero can serve with existing capabilities
Product portfolio or product category adjacencies that can increase wallet share
Newer service offerings that improve margin profile
Enhancement of geographical mix
Strengthening of market share in existing markets
Identification of a strong management team run by experienced promoters
Acquisitions happen at 0.3-0.35x revenue multiples. This pricing reflects the thin margins in distribution. Sellers are typically local distributors facing competitive pressure from national players and lacking capital for technology investments.
Of the 32 companies acquired between CY18 and CY22, approximately 30 grew revenue at 20-25% annually over the subsequent two to three years. The acquired entities typically have blended Ebitda margins of 6-8%, higher than Entero’s consolidated margins. Integrating these businesses improves the overall margin profile.
Entero’s established acquisition process is data-driven and well-tested. It can be replicated in existing markets and new geographies. This repeatable model allows continuous expansion through acquisitions.
Market Share Trajectory
Entero’s Market Share in Healthcare Distribution
Entero’s market share in the healthcare distribution market has grown from 0.8% in FY21 to 1.3% in FY24. The share gain reflects both organic outperformance and acquisitions. The combined market share of the three national distributors improved from 3-5% in 2015 to 8-10% currently. Industry participants expect this to reach 20-30% by FY28. This implies the national players will grow at 25-30% annually, taking share from local distributors.
Growth Triggers
Several factors support continued growth for national distributors.
The underlying IPM grows at 9-10% annually. Medical devices grow at 11-12%. This provides a 10-11% baseline growth rate for the distribution market.
Consolidation provides additional growth. As national players take share from local distributors, they grow faster than the market. The share shift from 8-10% to 20-30% over the next few years implies substantial above-market growth.
New product categories offer expansion opportunities. Medical devices, diagnostic equipment, consumables, and nutraceuticals carry higher margins than pharmaceuticals. Expanding into these categories improves both growth and margins.
Commercial services add revenue streams. Marketing, promotion, and data services for manufacturers generate fee income beyond distribution margins.
Geographic expansion remains available. Tier-2 and tier-3 cities remain underpenetrated by national distributors. Expanding into these markets adds new customers.
Acquisition opportunities continue. The fragmented market with 65,000 distributors provides targets. Local players facing competitive pressure and lacking capital for technology investment become acquisition candidates.
Risk Factors
Future acquisitions not yielding desired results: Entero acquires smaller distributors in strategic locations throughout India as a part of its growth strategy. Historically, acquisitions have delivered desired results. However, acquisitions may not yield desired results and meet targets. This could impact profitability and lead to lower-than-expected improvement in margins, which in turn will impact free cash flow generation.
Negative FCF not sustainable for long period: Cash flow generation has been negative since inception due to high working capital intensive nature of the business, thin margins, and the ‘buy & build’ strategy. The company might have to raise further debt/equity capital.
Competition from other national players: Keimed and PharmEasy compete for the same customers and acquisition targets. Intensified competition could reduce margins or increase acquisition prices.
Margin compression: Pharma manufacturers may pressure distributor margins. Retail pharmacies may demand better pricing. Competitive dynamics could prevent margin expansion.
Technology disruption: New distribution models could emerge. Direct-to-pharmacy platforms from manufacturers or e-pharmacy players could alter the competitive landscape.
Regulatory changes: Changes in pharmaceutical distribution regulations, pricing controls, or trade margins could affect the business model.
Dependence on key customers: Concentration of revenue with specific manufacturers or retail chains creates dependence. Loss of major relationships would affect growth.
The Industry Maturation Path
The pharma distribution industry in India appears to be following the consolidation path seen in other countries. In the US, the market consolidated from hundreds of distributors to three dominant players over several decades. AmerisourceBergen, Cardinal Health, and McKesson now control 90-95% of the market.
In Germany, five players control 95-97%. In China, consolidation brought the top four to 40-45% share, up from 30-35% before 2015.
India’s consolidation started later and remains in early stages. The top players moved from 3-5% share in 2015 to 8-10% currently. The trajectory toward 20-30% by FY28 would represent meaningful progress but would still leave India far less consolidated than developed markets.
The consolidation thesis rests on structural advantages of scale. Large distributors offer better service, lower costs, and technology capabilities that local players cannot match. This drives manufacturer and retailer preference for national players. The preference accelerates share gains, which reinforce the scale advantages.
Market Position Summary
Entero operates in a large market undergoing structural change. The Rs3.3 trillion healthcare distribution market grows at 10-11% annually. Consolidation is shifting share from 65,000 local distributors to three national players. Entero ranks among the top three national distributors. Its network of 104 warehouses, 86,200+ retail customers, 2,500+ manufacturer relationships, and 76,600+ SKUs provides national reach. Proprietary technology platforms enable operational efficiency and data services.
The acquisition strategy has proven effective. Forty-five entities acquired since inception, with approximately 30 showing 20-25% revenue growth post-acquisition. The process is repeatable and can drive continued expansion.
Organic growth consistently outperforms the market at 1.5-2x IPM growth. Share gains come from superior service levels, higher fill rates, and technology capabilities that local distributors cannot match. The margin profile has room to improve. Gross margins can expand through procurement efficiencies and product mix. Operating leverage can drive Ebitda margin expansion. The benchmark of Keimed’s 4.5-5% adjusted Ebitda margins suggests the potential.
The risks center on acquisition execution, working capital management, and competitive dynamics. The growth strategy consumes capital and depends on successful integration of acquired businesses. The consolidation thesis provides a structural tailwind. As long as national distributors maintain service advantages over local players, share gains should continue. The market appears early in a multi-year consolidation cycle that has played out in other countries.